(IN BRIEF) BioNTech has achieved a significant milestone in expanding mRNA vaccine manufacturing in Africa with the inauguration of its Kigali site, which includes the first manufacturing unit known as BioNTainer. This move is part of BioNTech’s broader efforts to … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Africa, BioNTainer, BioNTech, Dr. Jean Kaseya, H.E. Macky Sall, H.E. Paul Kagame, H.E. Ursula von der Leyen, Hon. Annalena Baerbock, Moussa Faki Mahamat, mRNA Vaccine, Prof. Ugur Sahin, Rwanda, Sierk Poetting, vaccine
(IN BRIEF) BioNTech, a leading biotechnology company, has formalized a multi-year strategic partnership with the State of Victoria in Australia, building upon a prior Letter of Intent established in October 2022. The collaboration aims to strengthen the local mRNA ecosystem … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Australia, BioNTainers, BioNTech, mRNA Ecosystem, partnership, Prof. Ugur Sahin, Sierk Poetting, sustainability, Victoria
(IN BRIEF) Pfizer and BioNTech have announced positive topline results from a Phase 1/2 study of their mRNA-based combination vaccine program for influenza and COVID-19. The lead formulations showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. … Read the full press release
Posted in Business, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Annaliesa Anderson, BioNTech, Combination Vaccine, Comirnaty, COVID-19, influenza, influenza A, influenza B, mRNA, partnership, Pfizer, Prof. Ugur Sahin, respiratory diseases, SARS-CoV-2 strains, sustainability, wellness
(IN BRIEF) BioNTech and the Coalition for Epidemic Preparedness Innovations (CEPI) have entered into a strategic partnership to develop an mRNA-based vaccine, BNT166, for the prevention of mpox (formerly monkeypox), an infectious disease that can have severe and life-threatening complications. … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Norway, Pharma & Biotech, Science
Tagged BioNTech, BNT166, CEPI, mpox Prevention, mRNA-Based Vaccine, partnership, Prof. Ugur Sahin, Richard Hatchett, sustainability
(IN BRIEF) Pfizer and BioNTech have received a recommendation for marketing authorization from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine. The recommendation includes the administration of a single … Read the full press release
Posted in Business, European Union, Germany, Government, Healthcare, Industrial, Management, Marketing, News, Pharma & Biotech, Science
Tagged Albert Bourla, BioNTech, Comirnaty, COVID-19 vaccine, EMA, Omicron XBB.1.5-Adapted, Pfizer, Prof. Ugur Sahin, Tozinameran
(IN BRIEF) BioNTech reported its second-quarter 2023 financial results and corporate update, highlighting significant pipeline advancements in oncology with the initiation of BNT316/ONC-392 Phase 3 pivotal trial and positive data updates across multiple technology platforms. The company also prepares for … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Management, News, Pharma & Biotech, Science
Tagged BioNTech, Financial, Jens Holstein, Omicron-Adapted COVID-19 Vaccine, oncology pipeline, partnership, Pfizer, Prof. Ugur Sahin
(IN BRIEF) BioNTech and OncoC4 have entered into an exclusive license and collaboration agreement to develop and commercialize OncoC4’s anti-CTLA-4 monoclonal antibody candidate, ONC-392. The candidate aims to delete immunosuppressive T cells in the tumor microenvironment but spare T cells … Read the full press release
Posted in Germany, Management, News, Pharma & Biotech, Science, Technology
Tagged anti-CTLA-4 monoclonal antibody, BioNTech, Germany, ONC-392, OncoC4, Prof. Ugur Sahin, T cells, Yang Liu
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?